CM
BPMC

Capula Management’s Blueprint Medicines BPMC Stock Holding History

Capula Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-156,114
Closed -$20M – 806
2025
Q2 		$20M Buy
+156,114
New +$16.2M 0.19% 23
2024
Q3 		– Sell
-7,939
Closed -$856K – 501
2024
Q2 		$856K Buy
+7,939
New +$795K 0.01% 176
2023
Q3 		– Sell
-10,280
Closed -$650K – 523
2023
Q2 		$650K Buy
+10,280
New +$559K 0.02% 229

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Capula Management's BPMC Position: Q3 2025 in Review

Capula Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 156,114 shares — an estimated $20M sold.

Capula Management first reported a position in BPMC in Q2 2023 and held it in 3 quarters. The position peaked at $20M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Capula Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Capula Management sold 156,114 Blueprint Medicines shares in Q3 2025, an estimated $20M.
  • Capula Management first reported a position in Blueprint Medicines in Q2 2023 and held it in 3 quarters.
  • Capula Management's Blueprint Medicines position peaked at $20M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Capula Management's 13F filing for Q3 2025, filed 14 Nov 2025.